Storage and handling
Other information Do not store above 30 o C or 86 o F
No7 Protect and Perfect Day Cream Sunscreen SPF 15
- Manufacturer
- Boots Retail USA Inc | The Boots Company PLC | BCM Ltd
- Effective date
- 2010-02-24
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 4
- Source
- full-release
- Hydrated at
- 2026-05-31 22:23:40
Label at a glance#
ProductNo7 Protect and Perfect Day Cream Sunscreen SPF 15
Active ingredientOCTINOXATE, AVOBENZONE, OCTISALATE
Label structure16 sections
Contacts and useful links#
Websitewww.boots.com
www.boots.com
www.boots.comLabel contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
Active ingredients Purpose
Octinoxate (6.0%) Sunscreens
Avobenzone (3.0%)
Octisalate (2.5%)
OTC - PURPOSE SECTION
Uses
- Provides moderate protection against the adverse effects of the sun
- Higher SPF gives more protection
WARNINGS AND PRECAUTIONS SECTION
Warnings
For external use only
When using this product
Keep out of eyes. If contact occurs rinse thoroughly with cold water
Avoid direct contact with fabric
OTC - ASK DOCTOR SECTION
Stop use and ask a doctor if rash or irritation develops and lasts.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep our of reach of children. If swallowed, get medical help.
INDICATIONS & USAGE SECTION
Directions
- After cleansing, toning and applying Protect and Perfect Beauty Serum, simply smooth into your face and neck with your fingertips, avoiding your eyes.
- Apply evenly at least 15 minutes before sun exposure.
- Reapply as required.
- Not intended for children under the age of 12.
- Not intended for protection while sunbathing.
STORAGE AND HANDLING SECTION
Other information
Do not store above 30oC or 86oF
INACTIVE INGREDIENT SECTION
Inactive ingredients
Aqua (Water), Glycerin, C12-15 alkyl benzoate, Butyrospermum parkii (Shea butter), Dimethicone, Isononyl Isononanoate, Cetyl alcohol, C18-36 acid glycol ester, Polyglyceryl-3 methylglucose distearate, Phenoxyethanol, Polyacrylamide, Sorbitan stearate, Mica, Polysorbate 20, Alcohol denat., C13-14 isoparaffin, Dimethiconol, Butylene glycol, Methylparaben, Potassium cetyl phosphate, Parfum (Fragrance), Ethylparaben, Laureth-7, Retinyl palmitate, Sucrose cocoate, Xanthan gum, Ascorbyl glucoside, Tetrasodium EDTA, Citric acid, Lupinus albus seed extract, Dimethylmethoxy chromanol, Carbomer, Phyllanthus emblica fruit extract, Potassium hydroxide, Ginkgo biloba leaf extract, BHT, Tocopherol, Butylparaben, Palmitoyl oligopeptide, Propylparaben, Isobutylparaben, Silica, Palmitoyl tetrapeptide-7, CI 77891 (Titanium dioxide)
OTC - QUESTIONS SECTION
USA: Questions? 1-866-75-BOOTS
DESCRIPTION SECTION
Renewed Radiance ...
Give your skincare routine a boost with our protecting daytime formula for hydrated, smoother, revitalised skin. Created to be used with our Protect and Perfect Beauty Serum for prolonged moisturisation and even better results. Smoothes the appearance of fine dehydration lines, leaving skin feeling firmer.
A rich formulation which contains SPF15 and our patent pending next generation antioxidant complex to help protect against damaging effects of free radicals. Formulated with our skin firming pro-retinol complex containing lipo-peptides to boost and maintain elasticity.
A little facial, every day ...
Use every morning after cleansing, toning and applying Protect and Perfect Beauty Serum. Simply smooth into your face and neck with your fingertips, avoiding your eyes.
To give your skin an extra helping hand, use Protect and Perfect Beauty Serum and Night Cream just before bedtime.
Dermatologically testedINFORMATION FOR PATIENTS SECTION
Mfd in the UK for BBI NG2 3AA. UK.
Dist in the USA by Boots Retail USA Inc. Stamford CT 06901
USA: Questions? 1-866-75-Boots
DESCRIPTION SECTION
Use this protecting and rejuvenating daytime moisturiser with our Protect and Perfect Beauty Serum to reveal smoother, revitalised skin. Smooth into your face and neck.
Avoid direct contact with eyes.
Hypo-allergenic.
Dermatologically tested.
OTC - ACTIVE INGREDIENT SECTION
ACTIVE INGREDIENTS:
Octisalate 2.5%, Octinoxate 6.0%, Avobenzone 3.0%
INFORMATION FOR PATIENTS SECTION
Boots
Mdf in the UK for/Fabriqué au R.-U. pour BBI NG2 3AA. UK
Dist in the USA by/aux É.U. par Boots Retail USA Inc. Stamford CT 06901
USA: Questions? 1-866-75-BOOTS
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
No7
Protect and Perfect
Protection et Perfection
Day Cream / Créme de Jour
Works with your Protect and Perfect Beauty Serum to reveal younger looking skin
Sunscreen SPF 15
Hypo-allergenic
Boots
50ml e 1.69 US Fl. Oz
P and P Day Cream carton.jpg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Protect and Perfect
Protection et Perfection
Day Cream
Créme de Jour
Sunscreen SPF15
50ml e 1.69 US Fl. Oz
P and P Day Cream carton.jpg
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68472-100-01 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-c423-621f-e053-dbdaa90a74ad | Carton and jar labelling |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68472-100-01 | No7 Protect and Perfect Day Cream Sunscreen SPF 15 | 1 in 1 CARTON | EMULSION | 1 | 4 | |
| 68472-100-01 | No7 Protect and Perfect Day Cream Sunscreen SPF 15 | 50 mL in 1 JAR | EMULSION | 50 | 4 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| AVOBENZONE | ACTIVE INGREDIENT | G63QQF2NOX | 4 | |
| OCTINOXATE | ACTIVE INGREDIENT | 4Y5P7MUD51 | 4 | |
| OCTISALATE | ACTIVE INGREDIENT | 4X49Y0596W | 4 | |
| AVOBENZONE | ACTIVE MOIETY | G63QQF2NOX | 4 | |
| OCTINOXATE | ACTIVE MOIETY | 4Y5P7MUD51 | 4 | |
| OCTISALATE | ACTIVE MOIETY | 4X49Y0596W | 4 | |
| ALPHA-TOCOPHEROL | INACTIVE INGREDIENT | H4N855PNZ1 | 4 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 4 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 4 | |
| BUTYLPARABEN | INACTIVE INGREDIENT | 3QPI1U3FV8 | 4 | |
| CARBOMER HOMOPOLYMER TYPE C | INACTIVE INGREDIENT | 4Q93RCW27E | 4 | |
| CETYL ALCOHOL | INACTIVE INGREDIENT | 936JST6JCN | 4 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 4 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 4 | |
| ETHYLPARABEN | INACTIVE INGREDIENT | 14255EXE39 | 4 | |
| GINKGO | INACTIVE INGREDIENT | 19FUJ2C58T | 4 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 4 | |
| ISOBUTYLPARABEN | INACTIVE INGREDIENT | 0QQJ25X58G | 4 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 4 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 4 | |
| POLYSORBATE 20 | INACTIVE INGREDIENT | 7T1F30V5YH | 4 | |
| POTASSIUM HYDROXIDE | INACTIVE INGREDIENT | WZH3C48M4T | 4 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 4 | |
| SHEA BUTTER | INACTIVE INGREDIENT | K49155WL9Y | 4 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 4 | |
| SORBITAN MONOSTEARATE | INACTIVE INGREDIENT | NVZ4I0H58X | 4 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 4 | |
| VITAMIN A PALMITATE | INACTIVE INGREDIENT | 1D1K0N0VVC | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 | |
| XANTHAN GUM | INACTIVE INGREDIENT | TTV12P4NEE | 4 |
Products#
Every source-derived product name is available through these pages.
- No7 Protect and Perfect Day Cream Sunscreen SPF 15
- Avobenzone , Octinoxate and Octisalate
- OCTINOXATE
- AVOBENZONE
- OCTISALATE
- WATER
- GLYCERIN
- SHEA BUTTER
- DIMETHICONE
- CETYL ALCOHOL
- PHENOXYETHANOL
- SORBITAN MONOSTEARATE
- POLYSORBATE 20
- BUTYLENE GLYCOL
- METHYLPARABEN
- ETHYLPARABEN
- VITAMIN A PALMITATE
- XANTHAN GUM
- CITRIC ACID MONOHYDRATE
- CARBOMER HOMOPOLYMER TYPE C
- POTASSIUM HYDROXIDE
- GINKGO
- BUTYLATED HYDROXYTOLUENE
- ALPHA-TOCOPHEROL
- BUTYLPARABEN
- PROPYLPARABEN
- ISOBUTYLPARABEN
- SILICON DIOXIDE
- TITANIUM DIOXIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68472-100 | 68472-100-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING / ORAL | 83 mg | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | SYRUP / ORAL | 28.4 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | DROPS / ORAL | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SOLUTION / INTRAVENOUS | 5 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, SOLUBLE / ORAL | 2 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYRUP / ORAL | 40 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / TOPICAL | 216 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GEL, METERED / TOPICAL | 4 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ENEMA / RECTAL | 0.18 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET, COATED / ORAL | 0.8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / EPIDURAL | 30 mg | ||
| SORBITAN MONOSTEARATE | SORBITAN MONOSTEARATE | NVZ4I0H58X | SUSPENSION / ORAL | 62.5 mg/5ml | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | TABLET, COATED / ORAL | 0.08 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, CHEWABLE / ORAL | 1.28 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ELIXIR / ORAL | 200 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET, EXTENDED RELEASE / ORAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET / ORAL | 1.8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| ETHYLPARABEN | ETHYLPARABEN | 14255EXE39 | SUSPENSION / ORAL | 8 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SOAP / TOPICAL | 1 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER / ORAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / IONTOPHORESIS | 0.02 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET / SUBLINGUAL | 0.13 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / BUCCAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / IONTOPHORESIS | 0.2 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | SUSPENSION / OPHTHALMIC | 0.5 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CREAM / TOPICAL | 80 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INFILTRATION | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RESPIRATORY (INHALATION) | 0.03 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | OINTMENT / OPHTHALMIC | 0.01 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CONCENTRATE / ORAL | 5.3 mg/1ml | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET / ORAL | 56 mg | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | CAPSULE / ORAL | 172 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | GEL / TOPICAL | 14 mg | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | CAPSULE, DELAYED RELEASE / ORAL | 5 mg | ||
| CARBOMER HOMOPOLYMER TYPE C | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | 4Q93RCW27E | EMULSION / TOPICAL | 6 mg | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | LIQUID / TOPICAL | 0.02 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / NASAL | 250 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, COATED / ORAL | 0.25 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | LOTION / TOPICAL | 2000 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / NASAL | 10 mg/1ml | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL / TOPICAL | 1.16 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | PASTE, DENTIFRICE / DENTAL | 0.4 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ENEMA / RECTAL | 0.02 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / PERINEURAL | 80 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | SOLUTION / TOPICAL | 15 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION/ DROPS / ORAL | 19 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CAPSULE, EXTENDED RELEASE / ORAL | 0.22 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg | ||
| CARBOMER HOMOPOLYMER TYPE C | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | 4Q93RCW27E | OINTMENT, AUGMENTED / TOPICAL | 23 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CAPSULE / ORAL | 1 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| c20ef608-54c8-4cf1-94d4-9a6eb42b5298 | c252a9ad-fd93-4841-bfbd-5c3c3f0e05cd | 2010-02-24 | Warnings | c20ef608-54c8-4cf1-94d4-9a6eb42b5298 c252a9ad-fd93-4841-bfbd-5c3c3f0e05cd |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.